Tuesday, July 1, 2025 7/1/2025

A NOVEL THERAPEUTIC FOR LIVER FIBROSIS

Award Number: R43AA020163
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2011
PERIOD OF PERFORMANCE END DATE: 08/31/2012

Group Awards By:

View Award Description

A NOVEL THERAPEUTIC FOR LIVER FIBROSIS - DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to alleviate the underlying cause of disease. Since liver disease is typically diagnosed following significant scar formation, adjuvant strategies that oppose the molecular and cellular program of fibrosis that drives liver disease and activate matrix degrading pathways are urgently required. A preponderance of preclinical data in models of fibrotic liver disease speaks to the beneficial effects of the naturally occurring peptide hormone Relaxin (H2R). Translation of these findings into clinical regimen has been painfully slow in large part due to the costs and logistical difficulties associated with commercial production of recombinant human H2R. To fully capitalize on the antifibrotic potential of H2R, Angion Biomedica Corp., NY and Chemical and Biopharmaceutical Laboratories (CBL, CO) have developed a library of H2R-like peptides in commercially viable quantities at a fraction of the cost associated with production of similar quantities of recombinant human H2R. Importantly, our preliminary studies suggest that these novel peptides share H2R-like bioactivity in vitro. The proposed SBIR Phase I program seeks to identify a lead antifibrotic candidate from within this library as a treatment for liver fibrosis. PUBLIC HEALTH RELEVANCE: Fibrotic liver disease is a major health and socioeconomic burden in the United States. Development of a clinically viable antifibrotic strategy against liver disease is of tremendous significance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2011 ( Subtotal = $269,158 )
2011	2011	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Alcohol Research Programs	000	1	9/16/2011	NEW	$269,158
														Subtotal = $269,158

Grand Total All Awards = $269,158

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A NOVEL THERAPEUTIC FOR LIVER FIBROSIS

Award Number: R43AA020163

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2011

PERIOD OF PERFORMANCE END DATE: 08/31/2012

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer